Payment overview · 2025
General Payments
$7,051.07
251 reported records · 42 companies
Healthcare provider profile · identity verified
Jaswinder Singh, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · KANSAS CITY, MO · NPI 1093747677
Verified facts
What the public records show
CMS Open Payments records show Jaswinder Singh, MD received $7,051.07 in general payments during 2025 across 251 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 79 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Braftovi, Calquence, Creon, Lenvima, Lonsurf, Venclexta, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Venclexta by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRAFTOVI as an associated drug or biological on 11961 records involving 4943 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Braftovi by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Calquence by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Pomalyst by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
Eisai Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Lenvima as an associated drug or biological on 16833 records involving 7014 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lenvima by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Alecensa as an associated drug or biological on 194 records involving 149 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Alecensa by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Venclexta by this doctor in 2024.
Genentech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 33 records involving 19 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Venclexta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Xarelto by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LENVIMA as an associated drug or biological on 66 records involving 58 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lenvima by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRAFTOVI as an associated drug or biological on 627 records involving 419 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Braftovi by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Xtandi by this doctor in 2024.
TAIHO ONCOLOGY, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LONSURF as an associated drug or biological on 4796 records involving 2963 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Lonsurf by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $2,333.12 | 33.1% | 24 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $698.34 | 9.9% | 33 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $482.39 | 6.8% | 32 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $366.55 | 5.2% | 18 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $354.52 | 5.0% | 16 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $316.08 | 4.5% | 15 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $282.07 | 4.0% | 15 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $195.07 | 2.8% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $187.45 | 2.7% | 12 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $160.50 | 2.3% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $152.71 | 2.2% | 7 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $111.86 | 1.6% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $106.09 | 1.5% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $103.28 | 1.5% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $98.77 | 1.4% | 5 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $75.12 | 1.1% | 4 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $71.90 | 1.0% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $70.03 | 1.0% | 4 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $59.31 | 0.8% | 3 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $59.01 | 0.8% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $58.45 | 0.8% | 3 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $58.11 | 0.8% | 3 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $58.11 | 0.8% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $57.77 | 0.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $54.74 | 0.8% | 3 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $52.51 | 0.7% | 3 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $50.39 | 0.7% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $37.58 | 0.5% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $36.26 | 0.5% | 2 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $34.85 | 0.5% | 1 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $31.96 | 0.5% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.31 | 0.4% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.13 | 0.4% | 1 | 2025 |
| Immunocore Limited | Unresolved — no canonical attribution shown | $29.76 | 0.4% | 2 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $27.22 | 0.4% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.17 | 0.3% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $19.29 | 0.3% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $16.72 | 0.2% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $16.45 | 0.2% | 1 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $15.16 | 0.2% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.95 | 0.2% | 1 | 2025 |
| Spectrum Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.01 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,360.08 | 249 |
| Consulting Fee | $1,675.00 | 1 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $354.52 | 16 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $316.08 | 15 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $235.12 | 9 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $234.17 | 13 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $202.76 | 8 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $199.19 | 8 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $187.45 | 12 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $182.12 | 8 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $166.06 | 5 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $164.10 | 13 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $160.50 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $151.60 | 6 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $139.81 | 5 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC | $139.13 | 5 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $138.25 | 3 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $136.07 | 12 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $136.07 | 12 | 2025 |
Source payment records
|
|||||
| XYNTHA Normalized: xyntha |
Biological | PFIZER INC. | $132.89 | 6 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $131.27 | 9 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $124.51 | 8 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $116.45 | 5 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech, Inc. | $111.86 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $103.55 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $103.24 | 8 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $98.77 | 5 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $89.55 | 5 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $88.06 | 3 | 2025 |
Source payment records
|
|||||
| BENEFIX Normalized: benefix |
Biological | PFIZER INC. | $76.38 | 4 | 2025 |
Source payment records
|
|||||
| HYMPAVZI Normalized: hympavzi |
Drug | PFIZER INC. | $76.38 | 4 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $75.12 | 4 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $73.77 | 8 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $71.90 | 3 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $71.90 | 3 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $71.27 | 4 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $70.03 | 4 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $60.07 | 3 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $59.31 | 3 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $59.01 | 3 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $58.11 | 3 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $58.11 | 3 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $58.11 | 3 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $57.77 | 3 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $57.75 | 3 | 2025 |
Source payment records
|
|||||
| Quzyttir Normalized: quzyttir |
Drug | TerSera Therapeutics LLC | $55.26 | 3 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $54.74 | 3 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $52.51 | 3 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $52.03 | 2 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $50.39 | 2 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $45.54 | 3 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $40.57 | 2 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $38.02 | 2 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $38.02 | 2 | 2025 |
Source payment records
|
|||||
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $34.85 | 1 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $31.96 | 1 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $30.13 | 1 | 2025 |
Source payment records
|
|||||
| KIMMTRAK Normalized: kimmtrak |
Drug | Immunocore Limited | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $28.92 | 3 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $27.22 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| XALKORI Normalized: xalkori |
Drug | ARRAY BIOPHARMA INC | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| ENJAYMO Normalized: enjaymo |
Drug | RECORDATI_RARE_DISEASES_INC. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| Kcentra Normalized: kcentra |
Biological | CSL Behring | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| Privigen Normalized: privigen |
Biological | CSL Behring | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Stimufend Normalized: stimufend |
Biological | Fresenius Kabi USA, LLC | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| VPRIV Normalized: vpriv |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| ROLVEDON Normalized: rolvedon |
Drug | Spectrum Pharmaceuticals Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRAFTOVI braftovi |
2025 | Braftovi | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CALQUENCE calquence |
2025 | Calquence | 2024 | 77 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Lenvima lenvima |
2025 | Lenvima | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LONSURF lonsurf |
2025 | Lonsurf | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | BRAFTOVI open payments reported associated product |
CMS Open Payments — General Payments 11961 supporting records · 4943 recipient NPIs · example record 1228794645 |
Braftovi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
77 | 14 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 41 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 41 |
| Eisai Inc. Exact reporting entity; no affiliate inference |
2025 | Lenvima open payments reported associated product |
CMS Open Payments — General Payments 16833 supporting records · 7014 recipient NPIs · example record 1244455619 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Alecensa open payments reported associated product |
CMS Open Payments — General Payments 194 supporting records · 149 recipient NPIs · example record 1211488956 |
Alecensa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Genentech, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 19 recipient NPIs · example record 1211488888 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
88 | 20 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LENVIMA open payments reported associated product |
CMS Open Payments — General Payments 66 supporting records · 58 recipient NPIs · example record 1237995778 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | BRAFTOVI open payments reported associated product |
CMS Open Payments — General Payments 627 supporting records · 419 recipient NPIs · example record 1228794592 |
Braftovi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| TAIHO ONCOLOGY, INC. Exact reporting entity; no affiliate inference |
2025 | LONSURF open payments reported associated product |
CMS Open Payments — General Payments 4796 supporting records · 2963 recipient NPIs · example record 1211403676 |
Lonsurf · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 696 | 194 |
| Anastrozole | Anastrozole | 435 | 107 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 399 | 133 |
| Abiraterone Acetate | Abiraterone Acetate | 330 | 57 |
| Gabapentin | Gabapentin | 249 | 73 |
| Potassium Chloride | Potassium Chloride | 191 | 75 |
| Eliquis | Apixaban | 177 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 155 | 41 |
| Tamoxifen Citrate | Tamoxifen Citrate | 149 | 41 |
| Alprazolam | Alprazolam | 126 | 35 |
| Bicalutamide | Bicalutamide | 103 | 38 |
| Xarelto | Rivaroxaban | 88 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 87 | 33 |
| Methylprednisolone | Methylprednisolone | 87 | 74 |
| Hydroxyurea | Hydroxyurea | 85 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | 26 |
| Ondansetron Odt | Ondansetron | 82 | 45 |
| Pregabalin | Pregabalin | 78 | 23 |
| Calquence | Acalabrutinib Maleate | 77 | 14 |
| Acyclovir | Acyclovir | 75 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 36 |
| Dexamethasone | Dexamethasone | 74 | 47 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 74 | 42 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 66 | 43 |
| Tramadol Hcl | Tramadol Hcl | 64 | 31 |
| Fentanyl | Fentanyl | 56 | 21 |
| Spironolactone | Spironolactone | 56 | 17 |
| Diazepam | Diazepam | 52 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 18 |
| Xtandi | Enzalutamide | 52 | 14 |
| Montelukast Sodium | Montelukast Sodium | 51 | 16 |
| Revlimid | Lenalidomide | 49 | 11 |
| Warfarin Sodium | Warfarin Sodium | 49 | 16 |
| Furosemide | Furosemide | 48 | 19 |
| Hydromorphone Hcl | Hydromorphone Hcl | 48 | 19 |
| Imatinib Mesylate | Imatinib Mesylate | 44 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 29 |
| Letrozole | Letrozole | 40 | 17 |
| Lonsurf | Trifluridine/Tipiracil Hcl | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 34 |
| Lenalidomide | Lenalidomide | 39 | suppressed |
| Methadone Hcl | Methadone Hcl | 39 | 11 |
| Methylphenidate Hcl | Methylphenidate Hcl | 38 | 12 |
| Nubeqa | Darolutamide | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 23 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | 24 |
| Enoxaparin Sodium | Enoxaparin Sodium | 35 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 14 |
| Levetiracetam | Levetiracetam | 33 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 30 | 13 |
| Brukinsa | Zanubrutinib | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | 15 |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Allopurinol | Allopurinol | 25 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 11 |
| Fluconazole | Fluconazole | 25 | 14 |
| Pomalyst | Pomalidomide | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Lenvima | Lenvatinib Mesylate | 23 | suppressed |
| Lisinopril | Lisinopril | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Venclexta | Venetoclax | 19 | suppressed |
| Verzenio | Abemaciclib | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Omeprazole | Omeprazole | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Alecensa | Alectinib Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tibsovo | Ivosidenib | 13 | suppressed |
| Braftovi | Encorafenib | 12 | suppressed |
| Deferasirox | Deferasirox | 12 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,051.07 · 251 records | AstraZeneca Pharmaceuticals LP | ADCETRIS, BENEFIX, BLENREP, BRAFTOVI, CABOMETYX, CALQUENCE, CARVYKTI, CREON, DARZALEX, DATROWAY, Doptelet, ELAHERE, ELREXFIO, EMRELIS, ENHERTU, ENJAYMO, EPKINLY, ERLEADA, Fabhalta, GOMEKLI, HYMPAVZI, IBRANCE, ICLUSIG, IMBRUVICA, IMFINZI, INJECTAFER, INQOVI, Itovebi, JEMPERLI, KEYTRUDA, KIMMTRAK, KISQALI, Kcentra, LIBTAYO, LONSURF, LORBRENA, LUTATHERA, LYNPARZA, Lenvima, MEKTOVI, MI CANCER SEEK, OJJAARA, OPDIVO, ORGOVYX, Orserdu, PADCEV, PLUVICTO, POTELIGEO, PROVENGE, PYRUKYND, Polivy, Privigen, Quzyttir, REBLOZYL, ROLVEDON, RYBREVANT, RYTELO, SARCLISA, SCEMBLIX, Stimufend, TALVEY, TALZENNA, TECVAYLI, TUKYSA, Tecentriq, Trodelvy, VENCLEXTA, VPRIV, Vyloy, WELIREG, XALKORI, XPOVIO, XTANDI, XYNTHA, Yescarta, ZEJULA, ZEPZELCA, Zoladex, clonoSEQ | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Braftovi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error